- AU$83.35m
- AU$84.47m
- AU$32.33m
Annual cashflow statement for Cyclopharm, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.396 | 0.45 | 1.29 | 1.4 | 1.38 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.63 | -6.66 | -7.2 | -12.6 | -17.3 |
| Capital Expenditures | -1.16 | -1.55 | -0.538 | -0.972 | -2.11 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | 0.03 | 0 | 5.11 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -1.16 | -1.55 | -0.508 | -0.972 | 3 |
| Financing Cash Flow Items | -1.66 | 0.446 | 0.142 | -1.14 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.2 | -0.726 | -1.02 | 22.2 | -1.12 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 27.4 | -8.95 | -8.57 | 8.84 | -13.9 |